1,3-Dibromobenzene
Appearance
![]() | |
![]() | |
![]() | |
Names | |
---|---|
IUPAC name
1,3-Dibromobenzene
| |
Other names
m-Dibromobenzene
| |
Identifiers | |
3D model (JSmol)
|
|
1904538 | |
ChEBI | |
ChemSpider | |
ECHA InfoCard | 100.003.250 |
EC Number |
|
363342 | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C6H4Br2 | |
Molar mass | 235.906 g·mol−1 |
Appearance | colorless liquid[1] |
Density | 1.9523 g/cm3 at 20.4 °C |
Melting point | −7.0 °C (19.4 °F; 266.1 K) |
Boiling point | 218–220 °C (424–428 °F; 491–493 K) |
Related compounds | |
Related compounds
|
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
1,3-Dibromobenzene (m-dibromobenzene) is an aryl bromide and isomer of dibromobenzene that is a colorless liquid at room temperature.[1]
Preparation
[edit]1,3-Dibromobenzene may be prepared by diazotization of 3-bromoaniline, followed by a Sandmeyer reaction with cuprous bromide.[2]
Uses
[edit]1,3-Dibromobenzene has been used as a starting material in the synthesis of antiviral Lufotrelvir, in human clinical trials for the treatment of COVID-19.[3] The first step is formylation of 1,3-dibromobenzene to 2,6-dibromobenzaldehyde, by lithiation with lithium diisopropylamide in THF, followed by quenching with dimethylformamide.
See also
[edit]References
[edit]- ^ a b "1,3-Dibromobenzene". PubChem.
- ^ Hartwell, Jonathan L. (1944). "o-Chlorobromobenzene". Organic Syntheses. 24: 22. doi:10.15227/orgsyn.024.0022.
- ^ Allais, Christophe; Bernhardson, David; Brown, Adam R.; Chinigo, Gary M.; Desrosiers, Jean-Nicolas; Dirico, Kenneth J.; Hotham, Ian; Jones, Brian P.; Kulkarni, Samir A.; Lewis, Chad A.; Lira, Ricardo; Loach, Richard P.; Morse, Peter D.; Mousseau, James J.; Perry, Matthew A.; Peng, Zhihui; Place, David W.; Rane, Anil M.; Samp, Lacey; Singer, Robert A.; Wang, Zheng; Weisenburger, Gerald A.; Yayla, Hatice G.; Zanghi, Joseph M. (3 February 2023). "Early Clinical Development of Lufotrelvir as a Potential Therapy for COVID-19". Organic Process Research & Development. 27 (12): 2223–2239. doi:10.1021/acs.oprd.2c00375. PMID 37552749. S2CID 256584424.
{{cite journal}}
: CS1 maint: date and year (link)